1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-methylpiperazine | 960126-84-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-methylpiperazine
• 英文别名: 1-[3-(4-chlorophenyl)-4-(pyridin-4-yl)-1H-pyrazol-5-yl]-3-methylpiperazine；1-[5-(4-chlorophenyl)-4-pyridin-4-yl-1H-pyrazol-3-yl]-3-methylpiperazine
• CAS: 960126-84-5
• 化学式: C₁₉H₂₀ClN₅
• 分子量: 353.854
• InChiKey: ROYXMGVXIACORO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  56.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  在 肼 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 生成 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-methylpiperazine
  参考文献：
  名称：

  Synthesis, Crystal Structure, and Activity of Pyrazole-Based Inhibitors of p38 Kinase

  摘要：

  A series of pyrazole inhibitors of p38 mitogen-activated protein (MAP) kinase were designed using a binding model based on the crystal structure of 1 (SC-102) bound to p38 enzyme. New chemistry using dithietanes was developed to assemble nitrogen-linked substituents at the 5-position of pyrazoles. Calculated log D was used in tandem with structure-based design to guide medicinal chemistry strategy and improve the in vivo activity of a series of molecules. The crystal structure of an optimized inhibitor, 4 (SC-806), in complex with p38 enzyme was obtained to confirm the hypothesis that the addition of a basic nitrogen to the molecule induces an interaction with Asp112 of p38 alpha. A compound identified from this series was efficacious in an animal model of rheumatic disease.

  DOI：

  10.1021/jm0611915

文献信息

• [EN] SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS<br/>[FR] PYRAZOLES SUBSTITUES UTILISES COMME INHIBITEURS DE LA KINASE p38
  申请人：SEARLE & CO

  公开号：WO2000031063A1

  公开（公告）日：2000-06-02

  A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula (IA), wherein R?1, R2, R3 and R4¿ are as described in the specification.

  本文描述了一类吡唑衍生物，用于治疗p38激酶介导的疾病。 特别感兴趣的化合物由公式（IA）定义，其中R?1，R2，R3和R4¿如规范中所述。
• Substituted pyrazoles as p38 kinase inhibitors
  申请人：——

  公开号：US20040176433A1

  公开（公告）日：2004-09-09

  A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula IA 1 wherein R 1 , R 2 , R 3 and R 4 are as described in the specification.

  本文描述了一类吡唑衍生物，用于治疗p38激酶介导的疾病。特别感兴趣的化合物由公式IA1定义，其中R1、R2、R3和R4如规范中所述。
• Substituted pyrazoles as P38 kinase inhibitors
  申请人：G.D. Searle LLC

  公开号：EP1500657A1

  公开（公告）日：2005-01-26

  A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula (IA), wherein R1, R2, R3 and R4 are as described in the specification.

  描述了一类吡唑衍生物用于治疗 p38 激酶介导的疾病。特别感兴趣的化合物由式（IA）定义、 其中 R1、R2、R3 和 R4 如说明书所述。
• SUBSTITUED PYRAZOLES AS P38 KINASE INHIBITORS
  申请人：G.D. SEARLE & CO.

  公开号：EP1144403A1

  公开（公告）日：2001-10-17
• SUBSTITUTED PYRAZOLES AS P38 KINASE INHIBITORS
  申请人：G.D. Searle LLC

  公开号：EP1144403B1

  公开（公告）日：2004-10-06